Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Ovarian Stromal and Germ Cell Tumors

  • Richard T. Penson
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_7007-3

Definition

Cancers arising from the stromal and germ cell layers of the ovary are rare, heterogeneous, difficult to study, and require specialized multidisciplinary management. They more commonly present in younger patients and have a high cure rate. These tumors are associated with serum biomarkers that are informative for diagnosis and surveillance. Surgery is often part of primary treatment, with staging and preservation of fertility as important priorities. Most patients with germ cell tumors require adjuvant chemotherapy (ovarian cancer chemotherapy) with bleomycin, etoposide, and cisplatin, as well as careful surveillance.

Characteristics

Within the sex-cord-stromal and germ cell tumors, a variety of histopathological subtypes exist, and together they account for approximately 5 % of ovarian neoplasms. They generally present unilaterally, at early stages, and have a relatively good prognosis, with the germ cell tumors being very sensitive to chemotherapy. Patient age can be a...

Keywords

Germ Cell National Comprehensive Cancer Network Germ Cell Tumor National Comprehensive Cancer Network Adnexal Mass 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Brown J, et al. (2014) Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors. Int J Gynecol Cancer 24(9 Suppl 3):S48–54Google Scholar
  2. Colombo N, Parma G, Zanagnolo V, Insigna A (2007) Management of ovarian stromal cell tumors. J Clin Oncol 25:2944–2951PubMedCrossRefGoogle Scholar
  3. Dark GG, Bower M, Newlands ES, Paradinas F, Rustin GJ (1997) Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 15:620–624PubMedGoogle Scholar
  4. Gershenson DM (2007) Management of ovarian germ cell tumors. J Clin Oncol 25:2938–2943PubMedCrossRefGoogle Scholar
  5. Mancari R, Portuesi R, Colombo N (2014) Adult granulosa cell tumours of the ovary. Curr Opin Oncol 26(5):536–41Google Scholar
  6. Shumer ST, Cannistra SA (2003) Granulosa cell tumor of the ovary. J Clin Oncol 21:1180–1189CrossRefGoogle Scholar
  7. Williams S, Blessing JA, Liao S, Ball H, Hanjani P (1994) Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol 12:701–706PubMedGoogle Scholar

See Also

  1. (2012) Actinomycin D. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 19. doi:10.1007/978-3-642-16483-5_46Google Scholar
  2. (2012) Adnexal mass. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 84–85. doi:10.1007/978-3-642-16483-5_6897Google Scholar
  3. (2012) Adjuvant. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 75. doi:10.1007/978-3-642-16483-5_107Google Scholar
  4. (2012) Agonist. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 113. doi:10.1007/978-3-642-16483-5_7003Google Scholar
  5. (2012) Androgens. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 178. doi:10.1007/978-3-642-16483-5_268Google Scholar
  6. (2012) Bilateral salpingo-oophorectomy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 397. doi:10.1007/978-3-642-16483-5_6901Google Scholar
  7. (2012) Biomarkers. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 408–409. doi:10.1007/978-3-642-16483-5_6601Google Scholar
  8. (2012) CA125. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 577–578. doi:10.1007/978-3-642-16483-5_761Google Scholar
  9. (2012) Carboplatin. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 641. doi:10.1007/978-3-642-16483-5_833Google Scholar
  10. (2012) Choriocarcinoma. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 825. doi:10.1007/978-3-642-16483-5_6908Google Scholar
  11. (2012) Combination chemotherapy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 952. doi:10.1007/978-3-642-16483-5_6902Google Scholar
  12. (2012) Doxorubicin. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1159. doi:10.1007/978-3-642-16483-5_1722Google Scholar
  13. (2012) Dysgenesis. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1177. doi:10.1007/978-3-642-16483-5_7009Google Scholar
  14. (2012) Dysgerminoma. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1177. doi:10.1007/978-3-642-16483-5_1759Google Scholar
  15. (2012) Epithelial ovarian cancer. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1292. doi:10.1007/978-3-642-16483-5_6952Google Scholar
  16. (2012) Estrogens. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1333. doi:10.1007/978-3-642-16483-5_2019Google Scholar
  17. (2012) FIGO. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1407. doi:10.1007/978-3-642-16483-5_2188Google Scholar
  18. (2012) Follicle-stimulating hormone. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1441. doi:10.1007/978-3-642-16483-5_2235Google Scholar
  19. (2012) Germ cell tumors. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1541. doi:10.1007/978-3-642-16483-5_6905Google Scholar
  20. (2012) Gonadoblastoma. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1577. doi:10.1007/978-3-642-16483-5_7010Google Scholar
  21. (2012) Gynecologic Oncology Group. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1617. doi:10.1007/978-3-642-16483-5_7017Google Scholar
  22. (2012) Hirsutism. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1696. doi:10.1007/978-3-642-16483-5_2738Google Scholar
  23. (2012) Human chorionic gonadotropin. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 1752–1753. doi:10.1007/978-3-642-16483-5_6914Google Scholar
  24. (2012) Inhibin. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1864. doi:10.1007/978-3-642-16483-5_3051Google Scholar
  25. (2012) Isochromosome. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1917. doi:10.1007/978-3-642-16483-5_3155Google Scholar
  26. (2012) KIT. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 1945–1946. doi:10.1007/978-3-642-16483-5_3228Google Scholar
  27. (2012) Luteinizing hormone. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 2115–2116. doi:10.1007/978-3-642-16483-5_6804Google Scholar
  28. (2012) Methotrexate. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2274. doi:10.1007/978-3-642-16483-5_3680Google Scholar
  29. (2012) Müllerian inhibiting substance. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2392. doi:10.1007/978-3-642-16483-5_7013Google Scholar
  30. (2012) National comprehensive cancer network. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 2457–2458. doi:10.1007/978-3-642-16483-5_7015Google Scholar
  31. (2012) Omentum. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2609. doi:10.1007/978-3-642-16483-5_4213Google Scholar
  32. (2012) POMB/ACE. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2958. doi:10.1007/978-3-642-16483-5_7016Google Scholar
  33. (2012) Progesterone. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2990. doi:10.1007/978-3-642-16483-5_4753Google Scholar
  34. (2012) Salvage chemotherapy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3334. doi:10.1007/978-3-642-16483-5_6947Google Scholar
  35. (2012) Schiller-Duval bodies. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 3340–3341. doi:10.1007/978-3-642-16483-5_6940Google Scholar
  36. (2012) Sertoli-Leydig cell tumor. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3390. doi:10.1007/978-3-642-16483-5_5266Google Scholar
  37. (2012) Surgical debulking. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3575. doi:10.1007/978-3-642-16483-5_5598Google Scholar
  38. (2012) Taxanes. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 3614–3615. doi:10.1007/978-3-642-16483-5_6648Google Scholar
  39. (2012) Teratoma. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3651. doi:10.1007/978-3-642-16483-5_5732Google Scholar
  40. (2012) Testosterone. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3660. doi:10.1007/978-3-642-16483-5_5741Google Scholar
  41. (2012) TSH. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3786. doi:10.1007/978-3-642-16483-5_6000Google Scholar
  42. (2012) Vinblastine. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3907. doi:10.1007/978-3-642-16483-5_6186Google Scholar
  43. (2012) Vincristine. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3908. doi:10.1007/978-3-642-16483-5_6188Google Scholar
  44. (2012) Yolk sac tumor. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 3973–3974. doi:10.1007/978-3-642-16483-5_7011Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg (outside the USA) 2014

Authors and Affiliations

  1. 1.Division of Hematology OncologyMassachusetts General HospitalBostonUSA